Literature DB >> 3951166

[The doubling time of circulating CEA as an individual prognostic criterion of recurrence in patients with gastrointestinal cancers].

T Brümmendorf, F A Anderer, H J Staab, A Hornung, G Kieninger.   

Abstract

In a prospective study of 928 patients with gastrointestinal cancer registered for primary resection, the postoperative carcinoembryonic antigen (CEA) time courses were analysed in connection with disease recurrence. Only patients with established diagnosis of disease recurrence and complete follow-up to death entered the evaluation of prognostic criteria of the CEA time course. In this group the CEA time courses of 103/201 patients with recurrent disease exhibited an exponential increase of the serum CEA concentration, i.e. a linear relationship of log CEA and time, which allowed the calculation of the CEA doubling time. All 103 patients developed metastatic spread and generally exhibited CEA doubling times ranging between 10 and 158 days, in patients developing peritoneal carcinosis up to 343 days. The individual CEA doubling times of patients with recurrent disease who received no treatment (n = 71) correlated well with the times of individual survival after the initial CEA increase of the log CEA phase (rs = 0.812; P less than 0.001) thus confirming the results of a previous retrospective study. When the survival time is expressed in multiples of the individual CEA doubling time (IDT), no patient survived longer than 10.8 IDT. The median value of survival was 5.4 IDT. Patients with metastatic spread who underwent various treatments of recurrent disease (n = 32) survived distinctly longer showing survival times up to 32.6 IDT. This could be confirmed by comparing the observed survival after the initial CEA increase of treated and untreated patients (life table method) exhibiting highly significant differences (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951166     DOI: 10.1007/bf01784131

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  17 in total

1.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

2.  Pre- and postoperative uses of CEA.

Authors:  J T Evans; A Mittelman; M Chu; E D Holyoke
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

3.  The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers.

Authors:  R Goslin; G Steele; J Macintyre; R Mayer; P Sugarbaker; K Cleghorn; R Wilson; N Zamcheck
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

4.  Circulating carcinoembryonic antigen (CEA), a growth parameter in malignant disease.

Authors:  H J Staab; F A Anderer
Journal:  Cancer Detect Prev       Date:  1983

5.  [Relapse prognosis for patients with adenocarcinoma of the gastrointestinal tract on the basis of carcinoembryonic antigen (CEA) and its circulating immune complexes (author's transl)].

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Klin Wochenschr       Date:  1980-02-01

6.  The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model.

Authors:  D Raghavan; J Gibbs; R Nogueira Costa; J Kohn; A H Orr; A Barrett; M J Peckham
Journal:  Br J Cancer Suppl       Date:  1980-04

7.  Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer.

Authors:  H J Staab; F A Anderer; T Brümmendorf; A Hornung; R Fischer
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

8.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

9.  Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model.

Authors:  J B Quayle
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

10.  Doubling time of circulating cea and its relation to survival of patients with recurrent colorectal cancer.

Authors:  H J Staab; F A Anderer; A Hornung; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

View more
  2 in total

1.  Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.

Authors:  F Tian; H E Appert; J Myles; J M Howard
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

Review 2.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.